Suppr超能文献

心脏手术围手术期输血与血液保护:胸外科医师协会和心血管麻醉医师协会临床实践指南

Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.

作者信息

Ferraris Victor A, Ferraris Suellen P, Saha Sibu P, Hessel Eugene A, Haan Constance K, Royston B David, Bridges Charles R, Higgins Robert S D, Despotis George, Brown Jeremiah R, Spiess Bruce D, Shore-Lesserson Linda, Stafford-Smith Mark, Mazer C David, Bennett-Guerrero Elliott, Hill Steven E, Body Simon

出版信息

Ann Thorac Surg. 2007 May;83(5 Suppl):S27-86. doi: 10.1016/j.athoracsur.2007.02.099.

Abstract

BACKGROUND

A minority of patients having cardiac procedures (15% to 20%) consume more than 80% of the blood products transfused at operation. Blood must be viewed as a scarce resource that carries risks and benefits. A careful review of available evidence can provide guidelines to allocate this valuable resource and improve patient outcomes.

METHODS

We reviewed all available published evidence related to blood conservation during cardiac operations, including randomized controlled trials, published observational information, and case reports. Conventional methods identified the level of evidence available for each of the blood conservation interventions. After considering the level of evidence, recommendations were made regarding each intervention using the American Heart Association/American College of Cardiology classification scheme.

RESULTS

Review of published reports identified a high-risk profile associated with increased postoperative blood transfusion. Six variables stand out as important indicators of risk: (1) advanced age, (2) low preoperative red blood cell volume (preoperative anemia or small body size), (3) preoperative antiplatelet or antithrombotic drugs, (4) reoperative or complex procedures, (5) emergency operations, and (6) noncardiac patient comorbidities. Careful review revealed preoperative and perioperative interventions that are likely to reduce bleeding and postoperative blood transfusion. Preoperative interventions that are likely to reduce blood transfusion include identification of high-risk patients who should receive all available preoperative and perioperative blood conservation interventions and limitation of antithrombotic drugs. Perioperative blood conservation interventions include use of antifibrinolytic drugs, selective use of off-pump coronary artery bypass graft surgery, routine use of a cell-saving device, and implementation of appropriate transfusion indications. An important intervention is application of a multimodality blood conservation program that is institution based, accepted by all health care providers, and that involves well thought out transfusion algorithms to guide transfusion decisions.

CONCLUSIONS

Based on available evidence, institution-specific protocols should screen for high-risk patients, as blood conservation interventions are likely to be most productive for this high-risk subset. Available evidence-based blood conservation techniques include (1) drugs that increase preoperative blood volume (eg, erythropoietin) or decrease postoperative bleeding (eg, antifibrinolytics), (2) devices that conserve blood (eg, intraoperative blood salvage and blood sparing interventions), (3) interventions that protect the patient's own blood from the stress of operation (eg, autologous predonation and normovolemic hemodilution), (4) consensus, institution-specific blood transfusion algorithms supplemented with point-of-care testing, and most importantly, (5) a multimodality approach to blood conservation combining all of the above.

摘要

背景

少数接受心脏手术的患者(15%至20%)消耗了手术中输注的80%以上的血液制品。必须将血液视为一种既有风险又有益处的稀缺资源。对现有证据进行仔细审查可为分配这一宝贵资源和改善患者预后提供指导。

方法

我们审查了所有与心脏手术期间血液保护相关的已发表证据,包括随机对照试验、已发表的观察性信息和病例报告。传统方法确定了每种血液保护干预措施的可用证据水平。在考虑证据水平后,使用美国心脏协会/美国心脏病学会分类方案就每种干预措施提出了建议。

结果

对已发表报告的审查确定了与术后输血增加相关的高风险特征。六个变量作为重要的风险指标脱颖而出:(1)高龄,(2)术前红细胞量低(术前贫血或体型小),(3)术前抗血小板或抗血栓药物,(4)再次手术或复杂手术,(5)急诊手术,以及(6)非心脏患者合并症。仔细审查发现了可能减少出血和术后输血的术前和围手术期干预措施。可能减少输血的术前干预措施包括识别应接受所有可用的术前和围手术期血液保护干预措施的高风险患者以及限制抗血栓药物。围手术期血液保护干预措施包括使用抗纤溶药物、选择性使用非体外循环冠状动脉搭桥手术、常规使用血液回收装置以及实施适当的输血指征。一项重要的干预措施是实施基于机构的多模式血液保护计划,该计划为所有医疗保健提供者所接受,并且涉及经过深思熟虑的输血算法以指导输血决策。

结论

根据现有证据,特定机构的方案应筛查高风险患者,因为血液保护干预措施可能对这一高风险亚组最有成效。现有的循证血液保护技术包括:(1)增加术前血容量的药物(如促红细胞生成素)或减少术后出血的药物(如抗纤溶药物),(2)保存血液的装置(如术中血液回收和血液节约干预措施),(3)保护患者自身血液免受手术应激的干预措施(如自体预存血和等容血液稀释),(4)辅以即时检验的共识性、特定机构的输血算法,以及最重要的(5)结合上述所有措施的多模式血液保护方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验